Time, Fuel, & Money

Why 90% of Drugs Fail: Proteomics, Precision & the Hidden Fix

Deborah "Deb", Vassili, Karim Season 1 Episode 18

The quiet revolution reshaping drug development

Episode 18 continues the BIO deep dive with Chandima Bandara of Precision Quantomics, tackling one of biotech’s biggest truths: most drugs fail—not because the ideas are bad, but because the data is incomplete.

The conversation explores why LC-MS/MS and quantitative proteomics might be the missing layer, how small companies are leapfrogging Big Pharma, and how Bullpen’s Money Ball is rewriting the blueprint for scientific storytelling. This is science + strategy + startup reality, all in one.

Topics:

  • Why drugs fail in preclinical stages
  • Proteomics as a decision-making engine
  • How small companies out-innovate large ones
  • Data, toxicity & smarter R&D
  • Scientific storytelling for investors

🙏 Special thanks to Bullpen for championing founders and creating spaces like “Money Ball” where community meets real traction.